Prevalence and Predictors of Pap Smear Cervical Epithelial Cell Abnormality among HIV-Positive and Negative Women Attending Gynecological Examination in Cervical Cancer Screening Center at Debre Markos Referral Hospital, East Gojjam, Northwest Ethiopia by Getinet, Melkamu et al.
Touro Scholar 
College of Osteopathic Medicine (TUC) 
Publications and Research College of Osteopathic Medicine 
2015 
Prevalence and Predictors of Pap Smear Cervical Epithelial Cell 
Abnormality among HIV-Positive and Negative Women Attending 
Gynecological Examination in Cervical Cancer Screening Center at 





Touro University California, eiman.mahmoud@tu.edu 
Abate Assefa 
Follow this and additional works at: https://touroscholar.touro.edu/tuccom_pubs 
 Part of the International Public Health Commons, and the Women's Health Commons 
Recommended Citation 
Getinet, M., Gelaw, B., Sisay, A., Mahmoud, E. A., & Assefa, A. (2015). Prevalence and predictors of Pap 
smear cervical epithelial cell abnormality among HIV-positive and negative women attending 
gynecological examination in cervical cancer screening center at Debre Markos referral hospital, East 
Gojjam, Northwest Ethiopia. BMC Clinical Pathology, 15 [Article 16]. 
RESEARCH ARTICLE Open Access
Prevalence and predictors of Pap smear
cervical epithelial cell abnormality among
HIV-positive and negative women attending
gynecological examination in cervical cancer
screening center at Debre Markos referral
hospital, East Gojjam, Northwest Ethiopia
Melkamu Getinet1, Baye Gelaw2, Abinet Sisay1, Eiman A. Mahmoud3 and Abate Assefa2*
Abstract
Background: Cervical cancer is the leading cause of cancer related death among women in developing countries.
Cervical cancer is preceded by cervical surface epithelial cell abnormalities (ECA) which can be detected by Pap
smear test. Simultaneous human papillomavirus and human immunodeficiency virus (HIV) infection increases
cervical cancer. Data on the prevalence and predictors of ECA among women in Ethiopia is limited. Hence, we
aimed to determine the prevalence and associated factors of ECA among women.
Methods: A comparative cross-sectional study was conducted among HIV+ and HIV- women attending
gynecological examination in cervical cancer screening center at the Debre Markos referral hospital. The study
subjects were stratified by HIV status and systematic random sampling method was used to recruit study
participants. Cervical smears were collected for Pap smear examination. Logistic regression analysis was employed
to examine the possible risk factors of cervical ECA.
Results: A total of 197 HIV+ and 194 HIV- women were enrolled in the study. The overall prevalence of cervical
ECA was 14.1 % of which the prevalence of atypical squamous cells undetermined significance (ASCUS), low grade
squamous intraepithelial lesion (SIL), high grade SIL, squamous cell carcinoma and ASC, cannot exclude high grade
SIL (ASCH) were 5.1, 3.8, 4.1 and 1.0 %, 0.0 % respectively. Significantly higher prevalence of ECA (17.8 %) was observed
among HIV+ women (COR 1.9, 95 % CI: 1.1 − 3.4, p = 0.036) as compared to HIV-women (10.3 %). Multiple
sexual partnership (AOR 3.2, 95 % CI: 1.1 − 10.0, p = 0.04), early ages of first sexual contact (<15 years) (AOR 5.2,
95 % CI: 1.5 − 17.9, p = 0.009), parity greater than three (AOR 10.9, 95 % CI: 4.2 − 16.8, p < 0.001) and long term
oral contraceptive pills (OCP) use (AOR 11.9, 95 % CI: 2.1 − 16.7, p = 0.02) were significant predictors of
prevalence of ECA.
Conclusions: Cervical ECA is a major problem among HIV-infected women. Lower CD4+ T-cell counts of below
350 cells/μl, HIV infection, multiple sexual partnership, early age at first sexual contact, parity greater than three
and long term OCP use were significant predictors of prevalence of ECA. Strengthening screening program in
HIV+ women should be considered.
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Background
Squamous intraepithelial lesions (SIL) are an abnormal
growth of squamous epithelial cells of the ecto-cervix.
Cervical epithelial cell abnormalities (ECA) represent a
spectrum of SIL that lie along the pathway, from mild-
to-severe dysplasia to invasive cancer [1]. Cervical
carcinoma develops gradually through well characterized
precursor lesions [2]. Greater than 99.7 % cervical
cancer is attributed by human papillomavirus (HPV)
infection. HPV usually causes a variety of benign papillo-
matous lesions of the skin and mucosal basal epithelium
[3, 4]. There are more than100 different HPV genotypes
[5]. Based on oncogenic potential, HPV is classified as
high-risk (HR) and low-risk (LR) oncogenic types. HR-
HPV types, HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 68 and 82, cause anogenital cancer [6], while infec-
tion with LR-HPV types, HPV 6 and 11, is associated
with benign genital warts. HR-HPV types are detected in
99 % of cervical cancer, and about 70 % of cervical
cancer is due to HPV 16 and 18 [7].
More than half of sexually active people become in-
fected with HPV during their lifetime [8]. It is estimated
that in Ethiopia about 33.6 % of women in the general
population has HPV infection [9]. Persistent infection
with HR-HPV types over time leads to the development
and progression of cervical intraepithelial neoplasia
(CIN). Not all women who acquire HPV infection do de-
velop CIN. Rather approximately 90 % of HPV infections
clear within 2 years [10]. The peak of HPV infection in
women occurs in the late teens and early twenties
following sexual exposure [11, 12]. Cervical cancer asso-
ciated with HPV infection also leads to infertility. There
is higher incidence of ECA among women complaining
of infertility [13].
Cervical ECA can be detected and classified by cyto-
logical screening methods. Well organized programmes
of regular gynecological screening and treatment of
precancerous lesions have been very effective in prevent-
ing cervical cancer [14, 15]. Cytological examination of
cervical scrapping from clinically suspicious cases by
Papanicolaou (Pap) cytological screening test can detect
cervical ECA. The Pap smear identifies any changes in
cells of the transformation zone of the cervix [16]. The
Bethesda System 2001 classifies ECA into atypical squa-
mous cell (ASC), low-grade squamous intraepithelial
lesion (LSIL), high-grade squamous intraepithelial lesion
(HSIL) and squamous cell carcinoma (SCC). ASC com-
prises: ASC of undetermined significance (ASCUS) and
ASC, cannot exclude HSIL (ASCH); LSIL encompasses:
HPV, mild dysplasia, and CIN1; while HSIL includes:
moderate and severe dysplasia, carcinoma in situ, CIN 2,
and CIN 3. These categories promote specificity in the
mode of treatment [17]. For patients with invasive le-
sions the stage of a cervical cancer is the most important
factor in the selection of treatment modality. For women
diagnosed with ASCUS and LSIL follow up with HPV-
DNA testing, Pap smear or colposcopy within certain
time interval is some of the management options. In
general, noninvasive SIL identified using Pap smear only,
are treated with superficial ablative procedures such as
cryotherapy or laser therapy [18].
On a global level, 75 % of women has abnormal
cervical cytology at least once in their life time which
may progress to cervical cancer. Cervical cancer is the
second most common women cancer worldwide of
which 80 % occurs in developing countries. The higher
prevalence of cervical ECA due to HPV was reported in
African countries [19–21]. Current estimates indicates
that in Ethiopia 4648 women are diagnosed annually
with cervical cancer and 3235 die from the disease [9].
Several factors such as number of sexual partners and age
of first sexual activity, smoking, immune-suppression, and
presence of other sexually transmitted infection (STI) can
increase the risk of developing cervical cancer [22].
Several studies revealed that human immunodeficiency
virus (HIV) infection is associated with an increased risk
of HPV related cervical ECA [23–25]. Mortality and
morbidity due to cervical cancer is higher among HIV
patients [26–28]. HIV infection and cervical cancer
among women in Ethiopia are major public health prob-
lems. More than 534,000 adult women are estimated to be
infected with HIV and at risk of developing cervical
cancer. However, Ethiopia has invested little in the infra-
structure, training, and laboratory capacity required for
successful cytological screening [29]. Though studies have
shown that the prevalence of ECA is more common
among HIV-infected than non HIV-infected women, such
data in Ethiopia is limited. For the development of a ra-
tional approach to the screening and the subsequent man-
agement of precancerous cervical lesion in HIV-infected
women, understanding of the specific risk factors associ-
ated with ECA occurrence among HIV- positive women is
very much important. The aim of this comparative study
was to determine the prevalence of ECA and risk factors
associated with its occurrence among HIV+ and HIV-
women attending the Debre Markos referral hospital.
Methods
Study setting and design
A comparative cross-sectional study was conducted
among HIV- and HIV + women attending at the Debre
Markos referral hospital cervical cancer screening center
from the 1st of March to the 30th of May, 2014. Debre
Markos referral hospital is located in Debre Markos
town in East Gojjam Zone 300 km North of Addis
Ababa. According to July 2014 zonal statistical agency
report, the town has an estimated population of 100,000.
The hospital has cervical cancer screening and treatment
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center. The screening service is provided for all HIV+
women. All women attending the Debre Markos
referral hospital during the study period for any
gynecological problem were eligible for the study.
Pregnant women, lactating women and women on
menstrual cycle were excluded from the study. The
sample size was determined using two population
proportion formula with the assumption of 95 %
confidence interval (CI), 5 % marginal error and
33.6 % prevalence of ECA among HIV-infected
women (15) and 10 % nonresponse rate. Since there
is no previous study done in Ethiopia among HIV-
women, the prevalence of ECA was assumed to be
50 %. Using this assumptions the final sample size
becomes 400 (200 HIV+ and 200 HIV- women).
During the study period there were a total of 1600
HIV- and 2000 HIV+ women attending gynecological
examination in cervical cancer screening center. The
study subjects from both groups were selected by
systematic random sampling method.
Socio-demographic and clinical information
Data was collected after obtaining written informed
consent from each participant. A pre-tested structured
questionnaire was used to collect socio-demographic
and clinical information needed for the study. Socio-
demographic and clinical information included in this
study were age, marital status, age at first sexual
intercourse, number of sexual partners, duration of
oral contraceptive pills (OCP) use, condom use,
alcohol use, smoking, prostitution, history of STI,
CD4 + T-cell count and parity.
Cytopathological examination
The cervical smear specimens were collected by
gynecologist. Cervical smears were taken with a
wooden applicator stick, smeared on a microscopic
slide, fixed immediately with 95 % ethanol and allowed
to air dry. The smears were stained with Pap stain,
examined and graded according to the criteria of
Bethesda classification system [17]. To ensure the
quality of Pap smear results, 20 randomly selected
patients were evaluated by gynecologist with colpo-
scopic examination and visual inspection. Moreover,
representative smears were reexamined by patholo-
gists at the University of Gondar hospital blinded from
the first results. In this regard 30 randomly selected
positive and negative slides were blindly rechecked by
a pathologist.
HIV test and CD4+ T cell count
HIV counseling and testing based the national guide-
line was offered to participants unaware of their HIV
status. Whole blood sample of 8 ml was collected from
each study subject for HIV testing and CD4+ T-cell
counts. HIV testing was done based on current national
rapid HIV testing algorithms. For all HIV+ women, CD4+
T-cell counts were determined by Fluorescent Activated
Cell Sorter (FACS) count (Becton Dickinson) at Debre
Markos referral hospital.
Statistical analysis
Data was initially registered in a registration book and
transferred to excel Microsoft spread sheet. Data was
cleaned and checked for completeness before analysis
using SPSS version 20 computer software. Descriptive
statistical analysis was used to determine the socio −
demographic and clinical characteristics of study partici-
pants and prevalence of cervical ECA. The prevalence of
ECA was stratified by study subjects’ HIV status. Associ-
ations of patient characteristics with ECA were assessed
using a series of bivariate logistic regression analysis.
Then, to control simultaneously for the possible con-
founding effects of the different variables; a multivari-
able model was fitted with stepwise variable selection
among variables having p-value ≤ 0.2 at bivariate
analysis. In both bivariate and multivariate analyses,
the associations were expressed in odds ratios (OR)
and 95 % CI. For all cases p-value <0.05 were consid-
ered statistically significant.
Ethical approval
The study was reviewed and approved by ethical review
committee of School of Biomedical and Laboratory
Sciences, College of Medicine and Health sciences,
University of Gondar and official permission was
obtained from Debre Markos referral hospital higher
management. A written informed consent was obtained
from each study participant. All Pap smear positive
results were referred to the department of obstetrics
and gynecology for immediate treatment. The patients
record were made anonymous and any identifying
information were removed prior to analysis. Individual
records were coded and accessed only by research
staff members.
Results
Consistency of microscopy and colposcopic examinations
Pap smear microscopic examination was undertaken ini-
tially by trained laboratory technologist. Results obtained
were compared with results obtained by a pathologist
and gynecologist for consistency. In this regard, ten posi-
tive Pap smeared slides were given to three of the
readers and examined blindly. There was no discrepancy
between the results of the laboratory technologist and
the pathologist or the gynecologist results except for one
sample that was diagnosed as LSIL by the laboratory
technologist but as ASCUS by the pathologist (Table 1).
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Socio-demographic data and clinical characteristics of the
patients
A total of 400 women (200 HIV+ and 200 HIV- women)
were enrolled in the study, but 9 patients (3 HIV+ and 6
HIV-) were excluded because the smears were not
adequate for evaluation. Therefore, further analyses were
restricted to 391 study subjects. The mean age of the
study subjects was 35.02 years with standard deviation
of ±8.41 years. Two hundred and thirty (58.8 %) of the
women were married, and only 65 (16.6 %) were
employed. Majority of the study participants (59.1 %)
were urban dwellers. Hundred and seventy six (45.0 %)
of the women had no formal education (Table 2).
The number of life time sexual partners, greater than
two, was higher in HIV+ women (66.6 %) as compared
to HIV- ones (33.6 %). First sexual contact at early age
(<18 years) was also higher among HIV+ women
(56.0 %) than HIV- women (44.0 %). About 26.1 % of
the study subjects had a history of STI. Two hundred
and sixty seven participants (68 %) were accustomed to
alcohol intake and 0.8 % was currently smoking. About
5.4 % of women used OCP for greater than 5 years and
only 14.8 % of the women used condom. The number of
parity greater than two was lower in HIV+ women
compared to that of HIV- women (Table 3).
Clinical examination and Pap smear results
Clinical investigation was also conducted for all study
subjects and 16.4 % (64/391) were found to have abnor-
mal clinical findings. Among patients who had abnormal
clinical results, 60.9 %( 39/64) were positive for HIV.
Abnormal vaginal discharge and contact bleeding
were the most common clinical findings. In 56
(14.3 %) of the women abnormal vaginal discharge
was observed, whereas 8 (2.0 %) of the women had
contact bleeding. Pap smear examination revealed that
55 (14.1 %) patients were positive for cervical ECA.
Higher prevalence of ECA (17.8 %) was observed in
HIV+ women, of which the prevalence of ASCUS was
5.6 % (n = 11), 0.0 % ASCH, 6.1 % LSIL (n = 12),
5.1 % HSIL (n = 10) and 1.0 % SCC (n = 2). On the
other hand, a 10.3 % cervical ECA prevalence was
found among HIV- women with a prevalence of
4.6 % (n = 9), 0(0.0 %), 1.5 % (n = 3), 3.1 % (n = 6) and
1.0 % (n = 2) for ASCUS, ASCH, LSIL, HSIL and SCC
respectively (Table 4).
The prevalence of cervical ECA was high (51.9 %)
among HIV+ women with CD4 + T-cell count <200
cells/μl. The prevalence of ECA among women with
CD4 + T-cell counts of 200–349 cells/μl and 350–500
cells/μl were 18.5 % (n = 10) and 12.7 % (n = 7),
respectively. On the other hand, relatively low preva-
lence (6.6 %) of ECA was found among women with
CD4 + T-cell count greater than 500/ μl (Fig. 1).
Risk factor analysis for cervical epithelial cell abnormality
Both bivariate and multivariate logistic regression
analyses were employed to determine factors associ-
ated with ECA. All variables tested in the bivariate
logistic regression analysis were entered into multi-
variate analyses if they have p-value of ≤0.2. The
highest prevalence of cervical ECA (25.0 %) was
observed in older age women (>45 years of old).
Moreover, bivariate analysis showed that the preva-
lence of ECA was significantly higher among patients
within the age groups of 30–45 years old and above
(crude odds ratio (COR) 2.5, 95 % CI: 1.2 − 5.1, p = 0.012;
COR 4.2, 95 % CI: 1.7 − 10.5, p = 0.002 respectively)
as compared to younger women. Residence, educa-
tional status, condom use, smoking and alcohol con-
sumption were not associated with the development
of ECA.
Table 1 Consistency of the results of the 3 readers
Sample No Reader A Reader B Reader C
Method Result Grade Method Result Grade Method Result Grade
20 Msy ECA 1 Msy ECA 1 Cpy ECA -
55 Msy ECA 2 Msy ECA 2 Cpy ECA -
90 Msy ECA 3 Msy ECA 3 Cpy ECA -
111 Msy ECA 1 Msy ECA 1 Cpy ECA -
146 Msy ECA 2 Msy ECA 2 Cpy ECA -
244 Msy ECA 2 Msy ECA 1 Cpy ECA -
281 Msy ECA 1 Msy ECA 1 Cpy ECA -
307 Msy ECA 1 Msy ECA 1 Cpy ECA -
331 Msy ECA 3 Msy ECA 3 Cpy ECA -
343 Msy ECA 1 Msy ECA 1 Cpy ECA -
Reader A trained data collector, Reader B pathologist, Reader C Gynecologist, Msy Microscopy, Cpy Colposcopy, ECA Epithelial cell abnormality, Grade 1 atypical
squamous cell undetermined significance, Grade 2 Low grade squamous intraepithelial lesion, Grade 3 High grade squamous intraepithelial lesion, Grade 4
squamous cell carcinoma
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The higher proportion of cervical ECA (63.6 %)
was accounted by HIV+ women. Even though HIV
infection was not found as an independent risk fac-
tor for ECA in multivariate analysis, in the bivariate
analysis it was significantly associated with develop-
ing ECA (COR 1.9, 95 % CI:1.1 − 3.4, P = 0.036). A
downward trend of the prevalence of ECA along the
increment of CD4+ T-cell counts was observed
among HIV+ women. Significantly higher prevalence
of ECA were observed in HIV+ women with CD4+
T-cell counts <200 cells/μl (adjusted OR (AOR) 14.1,
95 % CI: 6.7 − 16.4, p < 0.001) and between 200 and
349 cells/μl all (AOR 9.6, 95 % CI: 1.8 − 11.5, p = 0.008) as
compared to patients with CD4+ T-cell counts of above
500 cells/μl.
Women with a previous history of multiple lifetime
sexual partners (more than two), were at high risk for
developing ECA when compared to their counterparts
with one or two sexual partner (AOR 3.2, 95 % CI:
1.0 − 10, p = 0.048). Early age at first sexual contact
(<15 years) was also identified as a significant risk
factor for the development of ECA (AOR 5.2, 95 %
CI: 1.5− 17.9, p = 0.009). Association of marital status
for the development of ECA was analyzed. Widowed
(AOR3.2, 95 % CI: 1.2 − 8.8, p = 0.021) and divorced
(AOR 3.0; 95 % CI: 1.1 − 8.1; p = 0.029) women were
at higher risk than women who are married. Women
with high parity (parity greater than four) were ten
folds more likely to develop ECA (AOR10.9, 95 % CI;
4.2 − 16.8, p < 0.001) than women with parity lower
than three. OCP users for more than five years were
found to be at higher risk of developing ECA
(AOR11.9, 95 % CI: 2.1 − 16.7, p = 0.02) (Table 5).
Discussion
The study showed that microscopic examination of Pap
smear results by a trained laboratory technologist are
comparable with the microscopic examination results of
the same preparation observed by a pathologist. The
current accepted practice is for the Pap smear to be
examined by pathologist, while nurse responsibility is
collection of the sample of cervical cells, and the techni-
cian responsibility is to prepare the slides with the path-
ologist responsible for slide readings and final reporting
of findings. The comparable accuracy of the trained
technologist reports of the Pap smear to the pathologist
reports may indicate the possible utilization of trained
technicians in the interpretations of Pap smears at the
peripheral health facility where there is no pathologist.
In this study, 16.4 % of the women had abnormal
clinical findings. The most prevalent clinical finding
(13.4 %) was abnormal vaginal discharge but only 2.0 % of
the women had contact bleeding. Vaginal discharge is
often a normal and regular occurrence. There are, how-
ever, types of discharge that may suggest underlying infec-
tious etiology. Such abnormal discharge was considered
when the vaginal discharge was yellow or green in color,
chunky in consistency, and have a foul odor. Most abnor-
mal discharges in the study were caused by yeast or bac-
terial infection. The prevalence of abnormal gynecological
findings such as abnormal vaginal discharge and contact
bleeding of the current study was relatively lower than
abnormal clinical findings reported from India which was
20 % and 6.7 % respectively [30].
In this study, the overall prevalence of cervical ECA
based on Pap smear test was 14.1 % in which the preva-
lence of ASCUS, ASCH, LSIL, HSIL and SCC were 5.1,
0.0, 3.8, 4.1 and 1.0 % respectively. The prevalence of
ECA among HIV+ women was 17.8 % which is quite
Table 2 Socio-demographic characteristics of women attending
cervical cancer screening center at Debre Markos referral hospital
Characteristics HIV status Total n %
Positive n (%) Negative n (%)
Age( in year)
<30 73(49.0) 76(51) 149 38.1
30-45 102(51.5) 96(48.5) 198 50.6
>45 22(50.0) 22(50.0) 44 11.3
Marital status
Married 92(40.0) 138(60.0) 230 58.8
Single 10(32.3) 21(67.7) 31 7.9
Divorced 49(69.0) 22(31.0) 71 18.2
Widowed 46(78.0) 13(22.0) 59 15.1
Marital status
Orthodox 185(52.4) 168(47.6) 353 90.3
Muslim 5(31.2) 11(68.8) 16 4.1
Protestant 7(31.8) 15(68.2) 22 5.6
Residence
Rural 70(43.8) 90(56.2) 160 40.9
Urban 127(55.0) 104(45.0) 231 59.1
Educational status
Illiterate 96(54.5) 81(45.5) 176 45.0
Primary school 59(58.4) 41(40.6) 101 25.8
Secondary& above 42(37.2) 71(62.8) 113 28.9
Occupation
Employed 24(36.9) 41(63.1) 65 16.6
House wife/Farmer 81(41.9) 112(58.1) 193 49.4
No work 32(68.1) 15(31.9) 47 12.0
Daily laborer 20(90.9) 2(9.1) 22 5.6
Commercial sex worker 8(50.0) 8(50.0) 16 4.1
Others 32(66.7) 16(33.3) 48 12.3
HIV Human immunodeficiency virus
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higher than from that of ECA among HIV- women.
Relatively concordant results on the prevalence of ECA
among HIV-infected women were reported from
Tanzania (17 %) [31] and Thailand (15.4 %) consisting of
ASCUS 2.8 %, LSIL 8.5 %, and HSIL 3.5 % [32]. On the
other hand, lower prevalence of ECA (2.8 %) was
reported among Turkish women of which 2.2 % was
ASCUS, 0.5 % LSIL, 0.1 % HSIL and 0.0 % SCC [33]. In
different regions of Nigeria, Pap smear screening have
shown a lower prevalence of HPV induced cervical ECA
(7.6 − 13.2 %) [34, 35]. Similarly, based on Bethesda
System ECA classification, the study conducted in
Nigeria among young females indicated that the preva-
lence of ASCUS was 7 %, LSIL 12.2 %, HSIL 7.7 % and
SCC 0.7 % [35]. Another study among Italian women
also reported 2.8 % ASCUS, 6.2 % LSIL and 1.7 % HSIL
cervical cytological abnormalities [36]. In contrast,
higher prevalence of HPV induced cervical ECA was
observed in South Africa in which 41.7, 70.2 and 83 %
were ASCUS, LSILS and HSIL, respectively [21]. In
Fig. 1 Proportion of cervical epithelial cell abnormality (ECA)
compared with the CD4 + T-cell count level of HIV+ women.
Increasing prevalence of cervical ECA was observed along with
the concomitant decreasing of CD4 + T-cell count which indicates a
direct relationship between the occurrence of cervical ECA and
CD4 + T-cell count level
Table 4 The prevalence of epithelial cell abnormality among
women attending cervical cancer screening unit at Debre
Markos referral hospital
Cervical cytology result HIV status Total tested
Positive Negative n %
NIL 162(82.2 %) 174(89.7 %) 336 85.9
ECA 35(17.8 %) 20(10.3 %) 55 14.1
Types of ECA ASCUS 11(5.6 %) 9(4.6 %) 20 5.1
LSIL 12(6.1 %) 3(1.5 %) 15 3.8
HSIL 10(5.1 %) 6(3.1 %) 16 4.1
SCC 2(1.0 %) 2(1.0 %) 4 1.1
NIL Negative for intraepithelial lesion, ECA Cervical epithelial cell abnormality,
ASCUS atypical squamous cell undetermined significance, LSIL Low grade
squamous intraepithelial lesion, HSIL High grade squamous intraepithelial
lesion, SCC squamous cell carcinoma, HIV Human immunodeficiency virus
Table 3 Behavioral and clinical characteristics of women attending cervical cancer screening unit at Debre Markos referral hospital
Variable HIV status Total
Positive n (%) Negative n (%) N %
No. of life time sexual partner 1-2 106(41.7) 148(58.3) 254 65.0
>2 91(66.4) 46(33.6) 137 35.0
Age of 1st sexual contact <18 160(56.0) 126(44.0) 286 73.1
18-20 25(32.0) 53(68.0) 78 19.9
>20 12(44.4) 15(55.6) 27 6.9
Alcohol use Yes 142(53.2) 125(46.8) 267 68.3
No 55(44.4) 69(55.6) 124 31.7
Smoking Yes 2(66.7) 1(33.3) 3 0.8
No 195(50.3) 193(49.7) 388 99.2
History of STI Yes 66(64.7) 36(35.3) 102 26.1
No 131(45.3) 158(54.7) 289 73.9
Duration of OCP usage <5 years 43(55.8) 34(44.2) 77 19.7
>5 years 13(61.9) 8(38.1) 21 5.4
Condom use Always 40(69.0) 18(31.0) 58 14.8
Some times 52(46.8) 59(53.2) 111 28.4
Never 105(47.3) 117(52.7) 222 56.8
Parity ≤2 122(52.6)) 110(47.4) 232 59.3
3-4 39(49.4) 40(50.6) 79 20.2
>4 36(45.0) 44(55.0) 80 20.5
HIV Human immunodeficiency virus, OCP Oral contraceptive pills, STI Sexually transmitted infection
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another study carried among Turkish women, higher
prevalence of ECA (54.8 %) was observed. The preva-
lence of ASCUS was 36.7 %, LSIL 16.8 %, HSIL 1.3 %
[37]. The discrepancy in the prevalence of ECA
between these studies may be due to differences in
the study population. Higher prevalence of ECA
observed from our finding and the report from South
Africa may be due to the inclusion of high number of
HIV-infected women. HIV is reported as one of the
independent risk factor for development of cervical
ECA and cervical cancer.
Women in the age groups of 30 years and older
were at greater risk of developing ECA in the present
study. There are also some other study findings which
indicate that older age women had greater risk for
the development of ECA. Cervical cancer mortality,
Table 5 Bivariate and multivariate analysis of risk factors for cervical ECA among women attending cervical cancer screening unit at
Debre Markos referral hospital
Variables Cervical ECA COR (95 % CI) P AOR (95 % CI) P
Yes No
No (%) No (%)
Age (in year) <30 11(7.4) 138(92.6) 1 1
30-45 33(16.7) 165(83.3) 2.5(1.22, 5.11) 0.012 0.8(0.30, 2.09) 0.648
>45 11(25.0) 33(75.0) 4.2(1.67, 10.47) 0.002 0.6(0.18, 2.25) 0.493
Marital status Married 21(9.1) 209(90.9) 1 1
Single 1(3.2) 30(96.8) 0.3(0.04, 2.55) 0.290 1.2(0.11,12.43) 0.869
Divorced 15(21.1) 56(78.9) 2.7(1.29, 5.50) 0.008 3.2(1.19, 8.77) 0.021
Widowed 18(30.5) 41(69.5) 4.4(2.14, 8.91) 0.000 3.0(1.12, 8.09) 0.029
Education NFE 35(19.8) 142(80.2) 2.6(0.87, 7.69) 0.087 2.2(0.69, 6.67) 0.181
Primary 16(9.5) 152(90.5) 1 1
Occupation Employed 6(9.2) 59(90.8) 1 1
HW 28(18.3) 165(81.7) 1.8(0.29, 10.76) 0.275 0.4(0.10, 1.88) 0.536
DL 10(16.7) 50(83.3) 2.9(0.64, 12.86) 0.167 0.3(0.05, 1.86) 0.205
CSW 4(18.2) 18(81.8) 1.6(0.27,9.93) 0.004 0.1(0.01, 0.95) 0.046
Others 7(14.6) 41(85.4) 2.6(0.80, 8.25) 0.081 0.8(0.17, 1.16) 0.112
Age of 1st sex (in year) <15 42(23.5) 137(76.5) 7.7(2.68, 22.28) <0.001 5.2(1.49, 17.95) 0.009
15-18 9(8.4) 98(91.6) 2.3(069, 7.77) 0.173 2.4(0.61, 9.49) 0.208
>18 4(3.8) 101(96.2) 1 1
No. of sexual partner 1-2 21(8.3) 233(91.7) 1 1
3-4 34(24.8) 103(75.2) 3.6(1.84, 6.96) <0.001 3.2(1.00, 10.03) 0.048
History of STI Yes 21(20.6) 81(79.4) 1.9(1.06, 3.53) 0.029 1.5(0.67, 3.42) 0.314
No 34(11.8) 255(88.2) 1 1
OCP user (in year) <5 7(9.1) 70(90.9) 1 1
≥5 16(76.2) 5(23.8) 30.0(7.6, 118.37) <0.001 11.9(2.11, 16.69) 0.020
No 14(11.3) 110(88.7) 1 1
Parity ≤2 13(5.6) 219(94.4) 1 1
3-4 6(10.7) 50(89.3) 3.2(1.36, 7.30) 0.007 1.7(0.53, 5.44) 0.362
>4 36(35.0) 67(65.0) 7.9(3.67, 16.92) <0.001 10.9(4.16, 16.75) <0.001
HIV status Negative 20(10.3) 174(89.7) 1 1
Positive 35(17.8) 162(82.2) 1.9(1.04, 3.38) 0.036 1.4(0.62, 3.16) 0.410
CD4 + T-cell count (cells/ μl) <200 14(51.9) 13(48.1) 15.3(4.33, 54.31) <0.001 14.1(6.69, 16.4) <0.001
200-349 10(18.5) 44(81.5) 3.2(0.95, 11.01) 0.060 9.6(1.79, 11.54) 0.008
350-500 7(12.7) 48(87.3) 2.1(0.57, 7.52) 0.265 5.8(0.98,31.62) 0.052
>500 4(6.6) 57(93.4) 1 1
HIV Human immunodeficiency virus, COR crude odds ratio, AOR adjusted odds ratio, CI confidence interval, P p- value, OCP Oral contraceptive pills, STI Sexually
transmitted infection, NFE No formal education, CSW Commercial sex worker, HW House wife, DL Daily laborer
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usually occurring among unscreened women, in-
creases with age, with the maximum mortality rate
reported for white women between age 45 years and
70 years, and for black women in their 70s [38, 39].
Mortality among women with negative Pap smear screen-
ing is low at all ages. The prevalence of SCC and ASCUS
were 36.4 and 81.8 % respectively among women <30 years
of age. ASCUS was found to be highest in the youngest
age group women in this study.
The study participants were stratified by their HIV
status and data of 197 (50.4 %) HIV+ and 194
(49.6 %) HIV- women were analyzed. We found
higher prevalence of cervical ECA (17.8 %) among
HIV+ women as compared to HIV- women (10.3 %).
This finding was very similar to the study finding reported
from Brazil where ECA was more common in the HIV+
group (12.1 %) compared to the HIV- group (5.4 %) [40].
In a study finding reported from India, all cervical ECA
(26.35 %) were found among HIV+ women [41]. HIV in-
fection is one of the major risk factor that contributes for
the growth of cervical ECA. HIV leads to an increased risk
of CIN and cervical cancer [40]. Up to 20 % of HIV co-
infected patients develop HPV-induced premalignant
lesions of the uterine cervix within three years of HIV
diagnosis [42]. Progression of an untreated HPV-induced
dysplastic lesion can lead to invasive cervical cancer, an
AIDS defining illness [43].
Moreover, the prevalence of ECA in this study was
significantly higher among HIV+ women with lower
CD4 + T-cell counts of < 350 cells/μl. Statistically
significant downward trends of the prevalence of ECA
along the increment of CD4+ T-cell counts in HIV+
women was observed in the present study. Similarly,
higher prevalence of ECA among HIV+ women with
lower CD + T-cell counts of <200 cells/μl was re-
ported [40, 44]. There are study reports that docu-
mented the higher risk of cervical ECA when CD4+
T-cell counts fall below < 200 cells/μl [25, 28].
Decreased CD4+ T-cells count and increased HIV-
RNA levels are risk factors for CIN. In addition, it
has also been shown that with decreasing numbers of
CD4+ T-cells, there is an increase in both frequency
and severity of cervical dysplasia in HIV-infected
women [36, 45]. Significant correlation was reported
between low levels of CD4+ T-cells, high HIV-viral
load and risk of CIN [46]. A Brazilian study demon-
strated that immunosuppressed women had a higher
risk of lesion recurrence as compared to women with
a CD4+ T-cells count > 200 cells/μl [47].
In our study widowed (30.5 %) and divorced
(21.1 %) women were significantly at higher risk for
the development of ECA when compared to married
(9.1 %) women. This difference might be due to
divorced and widowed women may have multiple
sexual partners when compared to married women.
This finding is supported by the report from Ghana
in which higher prevalence of ECA (21.3 %) was
observed in polygamous women when compared to
monogamous women (13.9 %) [48]. In this study,
women with a history of STI were 1.5 times more
likely to develop cervical ECA than women with no
history of STI. Previous reports also demonstrated
that genital infections were risk factors for the acqui-
sition of HPV infection and the progression of
cervical cancer [35, 43, 44].
We identified earlier initiation of first sexual contact
(<15 years) as a significant risk factor for the development
of ECA. Women with previous history of multiple life
time sexual partners (more than two) were also at high
risk for developing ECA which is supported by the study
reported from Tanzania (44). Another most important
finding of this study was that women with higher parity
(greater than four) were 10.9 times more likely to develop
ECA as compared to women with parity less than three.
OCP users for more than 5 years had higher risk for the
presence of ECA than their counterparts. Similar study
supported that the prevalence of cervical cancer associated
death in Ghana [48] among OCP users was higher.
Limitation
The limitation of this study is that the number of
study participants is relatively small for an epidemio-
logical study; the results may only be applied to
Northwest Ethiopia. Most of the study subjects were
patients with gynecological problems which may not
represent the general population. The result of this
study also may not represent the hospital catchment
population for most of women attending the cervical
screening center are HIV+. The short duration of the
study did not allow the adequate follow up of the
disease progression. Moreover, the study didn’t further
assess the etiology of the ECA.
Conclusions
Women infected with HIV had a greater risk of devel-
oping cervical ECA than HIV- women. There was a
downward trend of the prevalence of ECA along the
increment of CD4+ T-cell counts among HIV-infected
women. Lower CD4+ T-cell counts of below 350 cells/μl,
earlier initiation of first sexual contact (at the age
of <15 years), parity greater than four, being widowed and
divorced, multiple sexual partnership (more than three
partners) and long term OCP use were significant
predictors of increased risk of cervical ECA. Hence,
cytological screening program should be targeting specif-
ically HIV+ women. Awareness creation on risk factors as
multiple sexual partnership and sexual initiation at earlier
age should be provided.
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